APAC nuclear imaging agents market to hit $1.1b by 2034

China made up over half of the region’s market in 2024.

The Asia-Pacific’s nuclear imaging agents market is expected to reach $1.1b by 2034, according to a GlobalData report.

The sector’s expansion is attributed to an ageing population, rising chronic disease burden, and government healthcare investments.

China made up over half of the region’s market in 2024, whilst Japan and India together comprised 23%.

The shift to hybrid imaging systems is driving steady investment in nuclear diagnostics, with manufacturers and service providers focusing on developing new tracers, said Prerna Gupta, Medical Devices Analyst at GlobalData.

Meanwhile, trained staff shortage, insufficient government health insurance in developing countries, and the high cost of advanced treatments challenge market growth.

“Increase in number of private healthcare and diagnostic centres, better reimbursement policies, and targeted workforce training programmes could enable more patients to access advanced therapies, supporting the market expansion,” Gupta added.